According to the Centers for Disease Control and Prevention, 1 in 9 women in the United States experience symptoms of postpartum depression. Looking at individual states, postpartum depression can affect as many as 1 in 5 women. In March 2019, the FDA approved the first postpartum depression drug, developed by Sage Therapeutics. Led by CEO Jeff Jonas, Sage Therapeutics created the treatment by taking a different approach toward mental health.